Market Research Logo

Male Hypogonadism - Pipeline Review, H2 2018

Male Hypogonadism - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Male Hypogonadism - Pipeline Review, H2 2018, provides an overview of the Male Hypogonadism (Male Health) pipeline landscape.

Male hypogonadism is a condition in which the body doesn't produce enough testosterone. Symptoms include fatigue, hot flashes, infertility, decrease in muscle mass and loss of bone mass (osteoporosis). Risk factors for hypogonadism include HIV/AIDS, Klinefelter syndrome, Kallmann syndrome, injury to testicles and untreated sleep apnea. Treatment includes hormone replacement.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Male Hypogonadism - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Male Hypogonadism (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Male Hypogonadism (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Male Hypogonadism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 3, 2, 4, 5, 2, 4 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Male Hypogonadism (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Male Hypogonadism (Male Health).
  • The pipeline guide reviews pipeline therapeutics for Male Hypogonadism (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Male Hypogonadism (Male Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Male Hypogonadism (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Male Hypogonadism (Male Health)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Male Hypogonadism (Male Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Male Hypogonadism (Male Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Male Hypogonadism - Overview
Male Hypogonadism - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Male Hypogonadism - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Male Hypogonadism - Companies Involved in Therapeutics Development
Antares Pharma Inc
Clarus Therapeutics Inc
Diurnal Group Plc
EndoCeutics Inc
Ferring International Center SA
Lipocine Inc
M et P Pharma AG
Medlab Clinical Ltd
Merck & Co Inc
Mereo Biopharma Group Plc
Repros Therapeutics Inc
TesoRx Pharma LLC
Viramal Ltd
Male Hypogonadism - Drug Profiles
chorionic gonadotropin ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
corifollitropin alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
enclomiphene citrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IAS-167A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Kisspeptin-10 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
leflutrozole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
leuprolide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Libidua - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone enanthate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone propionate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone undecanoate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone undecanoate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone undecanoate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone undecanoate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone undecanoate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VERU-722 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Male Hypogonadism - Dormant Projects
Male Hypogonadism - Discontinued Products
Male Hypogonadism - Product Development Milestones
Featured News & Press Releases
Jun 14, 2018: Acerus Announces Approval of NATESTO in South Korea
May 03, 2018: Aytu BioScience Provides Update on Natesto
Apr 05, 2018: Acerus to Present at the Next CHINABIO Partnering Forum
Apr 05, 2018: Antares Pharma Provides Update on XYOSTED
Mar 27, 2018: Antares Pharma Announces XYOSTED Regulatory Update
Mar 20, 2018: Aytu BioScience Presents New Research Findings for Natesto at the Endocrine Society’s 100th Annual Meeting
Mar 19, 2018: Mereo BioPharma Announces Positive Top-Line Results from Phase 2b Study of BGS-649 for the Treatment of Hypogonadotropic Hypogonadism in Obese Men
Mar 15, 2018: Ferring announces positive outcome of European Decentralised Procedure for Testavan, a treatment for men with hypogonadism
Feb 02, 2018: Acerus Pharma’s NATESTO to Be Listed for Public Reimbursement in Quebec, Building on Strong 28% Increase in Natesto’s Canadian Prescriptions in Q4
Jan 26, 2018: Repros Announces Negative Opinion From the EMA for Enclomiphene
Jan 16, 2018: Antares Pharma Provides XYOSTED Regulatory Update
Dec 21, 2017: Antares Pharma Provides Regulatory Update on XYOSTED
Dec 15, 2017: Repros Therapeutics Receives Feedback Following an Oral Explanation with the European Medicines Agency
Dec 06, 2017: Acerus Enters into Loan Facility to Support Anticipated Product Launch and Sales and Marketing Initiatives
Nov 30, 2017: Acerus Secures CDN$1.6M of New NATESTO Orders from Its U.S. Licensee Aytu Bioscience
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Male Hypogonadism, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Male Hypogonadism - Pipeline by Antares Pharma Inc, H2 2018
Male Hypogonadism - Pipeline by Clarus Therapeutics Inc, H2 2018
Male Hypogonadism - Pipeline by Diurnal Group Plc, H2 2018
Male Hypogonadism - Pipeline by EndoCeutics Inc, H2 2018
Male Hypogonadism - Pipeline by Ferring International Center SA, H2 2018
Male Hypogonadism - Pipeline by Lipocine Inc, H2 2018
Male Hypogonadism - Pipeline by M et P Pharma AG, H2 2018
Male Hypogonadism - Pipeline by Medlab Clinical Ltd, H2 2018
Male Hypogonadism - Pipeline by Merck & Co Inc, H2 2018
Male Hypogonadism - Pipeline by Mereo Biopharma Group Plc, H2 2018
Male Hypogonadism - Pipeline by Repros Therapeutics Inc, H2 2018
Male Hypogonadism - Pipeline by TesoRx Pharma LLC, H2 2018
Male Hypogonadism - Pipeline by Viramal Ltd, H2 2018
Male Hypogonadism - Dormant Projects, H2 2018
Male Hypogonadism - Discontinued Products, H2 2018
List of Figures
Number of Products under Development for Male Hypogonadism, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Targets, H2 2018
Number of Products by Stage and Targets, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report